Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Palatin Technologies Inc PTN

Healthcare Biotechnology
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its new product development activities focus... see more

Recent & Breaking News (NYSEAM:PTN)

Palatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023

PR Newswire February 10, 2023

Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease

PR Newswire January 19, 2023

Palatin Receives $4.7 Million of Non-Dilutive Funding

PR Newswire January 18, 2023

Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions

PR Newswire January 10, 2023

Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results

PR Newswire January 5, 2023

Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

PR Newswire November 14, 2022

Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022

PR Newswire November 9, 2022

Palatin Announces $10 Million Registered Direct Offering

PR Newswire October 31, 2022

Palatin Presents PL8177 Data at American College of Gastroenterology Annual Meeting

PR Newswire October 24, 2022

First Patient Enrolled in Palatin's Phase 2 study of PL8177 in Ulcerative Colitis Trial

PR Newswire October 20, 2022

Palatin Announces Publication of Vyleesi® (bremelanotide) fMRI Study in Women with Hypoactive Sexual Desire Disorder (HSDD)

PR Newswire October 17, 2022

Palatin Announces Preliminary First Quarter Fiscal 2023 Vyleesi® Product Sales Results

PR Newswire October 13, 2022

Palatin Announces Presentation at the Eyecelerator@AAO 2022 Conference

PR Newswire September 29, 2022

Palatin to Participate in Ladenburg Thalmann Healthcare Conference

PR Newswire September 29, 2022

Palatin Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update

PR Newswire September 22, 2022

Palatin to Report Fourth Quarter and Fiscal Year End 2022 Results; Teleconference and Webcast to be held on September 22, 2022

PR Newswire September 19, 2022

Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis

PR Newswire September 8, 2022

Palatin Announces Intent to Effect Reverse Stock Split

PR Newswire August 19, 2022

Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease

PR Newswire August 16, 2022

Palatin Announces Preliminary Fourth Quarter Vyleesi® Net Product Revenue Increased 225% Over Prior Quarter

PR Newswire July 26, 2022